Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1994-7-20
|
pubmed:abstractText |
An anti-gastric cancer monoclonal antibody MGb2-mitomycin C conjugate via dextran T-70 as intermediate (MGb2-PAD-MMC) was produced, and 28-30 g molecules of MMC were introduced into 1 g molecule of MGb2. Ninety-six hours after ip of 125I-MGb2-PAD-MMC (1.48 MBq/22 micrograms MGb2 per mouse) to nude mice bearing human gastric cancer SGC-7901, the tumor tissue:blood (T/NT) radioactivity ratio was 2.6, very much higher than that of the control 125I-normal IgG-PAD-MMC group (T/NT = 0.20). Single photo computed tomography imaging confirmed the results of biodistribution study. MGb2-PAD-MMC exhibited selective killing action on the SGC-7901 cells in vitro, which was considered to be mediated by monoclonal antibody MGb2. Nude mice inoculated with SGC-7901 xenograft in bilateral subrenal capsule were treated by MMC (ip), human recombinant interferon-alpha (Hu-IFN-alpha im), MGb2-PAD-MMC (ip) and MGb2-PAD-MMC+Hu-IFN-alpha daily for 5 d beginning 4 h after inoculation. The efficacy of the reagents estimated by the reduction of tumor size and calculated by T/C (%), was 28.3%, 16.4%, 47.8%, and 83.1%, respectively. These results demonstrated that the antitumor effect of MGb2-PAD-MMC was superior to free MMC, and that the Hu-IFN-alpha might further enhance the action of MGb2-PAD-MMC.
|
pubmed:language |
chi
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Immunotoxins,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Mitomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0253-9756
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
572-6
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8010062-Adenocarcinoma,
pubmed-meshheading:8010062-Animals,
pubmed-meshheading:8010062-Antibodies, Monoclonal,
pubmed-meshheading:8010062-Humans,
pubmed-meshheading:8010062-Immunotoxins,
pubmed-meshheading:8010062-Interferon Type I,
pubmed-meshheading:8010062-Mice,
pubmed-meshheading:8010062-Mice, Inbred BALB C,
pubmed-meshheading:8010062-Mice, Nude,
pubmed-meshheading:8010062-Mitomycin,
pubmed-meshheading:8010062-Recombinant Proteins,
pubmed-meshheading:8010062-Stomach Neoplasms,
pubmed-meshheading:8010062-Subrenal Capsule Assay,
pubmed-meshheading:8010062-Tumor Cells, Cultured
|
pubmed:year |
1993
|
pubmed:articleTitle |
[Effect of targeting treatment of mitomycin C immunoconjugate on stomach neoplasm].
|
pubmed:affiliation |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
|
pubmed:publicationType |
Journal Article,
English Abstract,
Research Support, Non-U.S. Gov't
|